The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Pharmaceutical giant Novavax on Monday announced that the U.S. Food and Drug Administration (FDA) approved its COVID-19 ...

The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...

The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.

Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with ...

The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...

Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is ...